Milan, Italy, May 2026 — DiaSorin has appointed Gabriele Allegri as President of its Immuno Division, marking a significant leadership addition as the company continues to strengthen its precision medicine, companion diagnostics, and global immunodiagnostics capabilities. With more than two decades of leadership across pharmaceuticals, diagnostics, and MedTech, Allegri brings extensive expertise in commercial strategy, precision medicine, oncology, immunology, and global healthcare transformation.
Prior to joining DiaSorin, Allegri served as Vice President, Global Commercial Precision Medicine at Johnson & Johnson Innovative Medicine, where he played a central role in advancing global precision medicine strategies and companion diagnostics integration.
Before this, he held several senior leadership roles across Johnson & Johnson, including Global Commercial Head – Precision Medicine, General Manager – Johnson & Johnson Diabetes Care Italy, and multiple franchise leadership positions across immunology, infectious diseases, oncology, and CNS portfolios. Over his long tenure, he drove business transformation, global commercialization, market access strategies, and large-scale healthcare innovation.
Allegri’s industry influence also extends to governance and strategic advisory through leadership positions such as Board Chair of the Precision Cancer Consortium, Director on the Board of Personalized Medicine Coalition, and advisory roles focused on precision healthcare advancement.
Earlier in his career, he held strategic consulting and business leadership roles at Accenture, MicroStrategy, and Exor International, building a diverse foundation across healthcare strategy, business development, and commercial innovation.
His appointment reflects DiaSorin’s commitment to expanding its leadership in specialty diagnostics, immunodiagnostics, and life sciences while accelerating innovation in precision medicine.
About DiaSorin
DiaSorin, headquartered in Italy and listed on the FTSE MIB Index, is a global leader in the in vitro diagnostics (IVD) and life sciences sectors. Operating in over 35 countries with more than 3,200 employees, DiaSorin develops, manufactures, and markets advanced diagnostic solutions, offering one of the broadest specialty testing portfolios worldwide.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
